NCT05748171 2026-02-03A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLPfizerPhase 2 Recruiting100 enrolled
NCT03677596 2023-11-22A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsPfizerPhase 4 Completed102 enrolled 27 charts